Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas

PRIMARY OBJECTIVE: I. Determine the efficacy of duvelisib maintenance therapy in peripheral T-cell lymphoma (PTCL) patients who have achieved a complete response (CR) following first-line treatment and are either ineligible for or decline consolidative autologous stem cell transplantation (ASCT). SECONDARY OBJECTIVE: I. Determine the tolerability and preliminary survival outcomes of duvelisib maintenance therapy. EXPLORATORY OBJECTIVE: I. Examine the association between biomarkers (e.g., minimal residual disease \[MRD\]) and clinical outcomes (overall response rate \[ORR\], progression free survival \[PFS\]). OUTLINE: Patients receive duvelisib orally (PO) twice daily (BID) on days 1-28 of each cycle. Cycles repeat every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients who remain in continuous complete response may continue to receive duvelisib for an additional 13 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow aspiration and biopsy during screening, as well as positron emission tomography (PET)/computed tomography (CT) scans and blood sample collection throughout the study. Patients may also undergo bone marrow aspiration and biopsy on study. After completion of study treatment, patients are followed up at 4-6 weeks, then periodically for up to 5 years.